#### <sup>1</sup>**Associations of Combined Phenotypic Aging and Genetic Risk with Incident**

#### <sup>2</sup>**Cancer: A Prospective Cohort Study**

- 3
- 4 Lijun Bian<sup>1,2†</sup>, Zhimin Ma<sup>1†</sup>, Xiangjin Fu<sup>1</sup>, Chen Ji<sup>1</sup>, Tianpei Wang<sup>1</sup>, Caiwang Yan<sup>1,2,3</sup>,
- 5 Juncheng Dai<sup>1,2</sup>, Hongxia Ma<sup>1,2</sup>, Zhibin Hu<sup>1,2</sup>, Hongbing Shen<sup>1,2,4</sup>, Lu Wang<sup>3\*</sup>, Meng 6 Zhu<sup>1,2,3\*</sup>, Guangfu Jin<sup>1,2,3\*</sup>
- 
- $10^{-1}$  Department of Epidemiology, Center for Global Health, School of Public Health,
- <sup>9</sup>Nanjing Medical University, Nanjing, China.
- $2^2$  Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative
- 11 Innovation Center for Cancer Personalized Medicine and China International
- 12 Cooperation Center for Environment and Human Health Nanjing Medical University,
- 13 Nanjing, China.
- $3^3$  Department of Chronic Non-Communicable Disease Control, The Affiliated Wuxi
- <sup>15</sup>Center for Disease Control and Prevention of Nanjing Medical University, Wuxi
- 16 Center for Disease Control and Prevention, Wuxi Medical Center, Nanjing Medical
- 17 University, Wuxi, China.
- <sup>4</sup> Research Units of Cohort Study on Cardiovascular Diseases and Cancers, Chinese
- 19 Academy of Medical Sciences, Beijing, China.
- $20$
- 21  $\text{†}$  These authors contributed equally to this work.
- <sup>\*</sup> **Correspondence to:** Prof Guangfu Jin, Department of Epidemiology, Center for
- <sup>23</sup>Global Health, School of Public Health, Nanjing Medical University, 101 Longmian
- <sup>24</sup>Rd., Nanjing 211166, China. Email: guangfujin@njmu.edu.cn; or Prof Meng Zhu,
- 25 Department of Epidemiology, Center for Global Health, School of Public Health,
- <sup>26</sup>Nanjing Medical University, 101 Longmian Rd., Nanjing 211166, China. E-mail:

- 27 zhmnjmu@njmu.edu.cn; or Prof Lu Wang, Department of Chronic
- 28 Non-Communicable Disease Control, Wuxi Center for Disease Control and
- 29 Prevention, Affiliated Wuxi Center for Disease Control and Prevention of Nanjing
- <sup>30</sup>Medical University, 499 Jincheng Rd., Wuxi 214023, China. E-mail:
- <sup>31</sup>wanglu123@njmu.edu.cn.

### <sup>32</sup>**Abstract**

#### <sup>33</sup>**Background**

- <sup>34</sup>Age is the most important risk factor for cancer, but aging rates are heterogeneous
- 35 across individuals. We explored a new measure of aging-Phenotypic Age
- <sup>36</sup>(PhenoAge)-in the risk prediction of site-specific and overall cancer.

#### <sup>37</sup>**Methods**

- <sup>38</sup>Using Cox regression models, we examined the association of Phenotypic Age
- <sup>39</sup>Acceleration (PhenoAgeAccel) with cancer incidence by genetic risk group among
- <sup>40</sup>374,463 participants from the UK Biobank. We generated PhenoAge using
- 41 chronological age and 9 biomarkers, PhenoAgeAccel after subtracting the effect of
- <sup>42</sup>chronological age by regression residual, and an incidence weighted overall cancer
- <sup>43</sup>polygenic risk score (CPRS) based on 20 cancer site-specific polygenic risk scores <sup>44</sup>(PRSs).

# <sup>45</sup>**Results**

- <sup>46</sup>Compared with biologically younger participants, those older had a significantly
- 47 higher risk of overall cancer, with hazard ratios (HRs) of  $1.22$  (95% confidence
- 48 interval,  $1.18-1.27$ ) in men,  $1.26$  (1.22-1.31) in women, respectively. A joint effect of
- <sup>49</sup>genetic risk and PhenoAgeAccel was observed on overall cancer risk, with HRs of
- <sup>50</sup>2.29 (2.10-2.51) for men and 1.94 (1.78-2.11) for women with high genetic risk and
- 51 older PhenoAge compared with those with low genetic risk and younger PhenoAge.
- 52 PhenoAgeAccel was negatively associated with the number of healthy lifestyle factors
- 53 (Beta =  $-1.01$  in men,  $P < 0.001$ ; Beta =  $-0.98$  in women,  $P < 0.001$ ).

#### <sup>54</sup>**Conclusions**

<sup>55</sup>Within and across genetic risk groups, older PhenoAge was consistently related to an 56 increased risk of incident cancer with adjustment for chronological age and the aging 57 process could be retarded by adherence to a healthy lifestyle.

<sup>58</sup>**Key Words:** Phenotypic aging; Polygenic risk score; Healthy lifestyle; Cancer risk.

# <sup>59</sup>**Introduction**

<sup>60</sup>Cancer continues to be the leading cause of death globally and the reduction of 61 cancer-related deaths remains to be a public health priority (Bray et al., 2018). The <sup>62</sup>morbidity and mortality of cancer increase dramatically with age, which demonstrated 63 that aging is the greatest risk factor for cancer (Siegel, Miller,  $\&$  Jemal, 2018). <sup>64</sup>Although everyone gets older, individuals are aging at different rates (Rutledge, Oh, <sup>65</sup>& Wyss-Coray, 2022). Therefore, the variation in the pace of aging between-person <sup>66</sup>may reflect the differences in susceptibility to cancer and death. Thus, measurement <sup>67</sup>of an individual's biological age, particularly at the early stage of life, may promote 68 the primary and secondary prevention of cancer through earlier identification of high 69 risk groups. <sup>70</sup>Recently, Morgan and colleagues developed and validated a novel multi-system-based <sup>71</sup>aging measurement (Levine et al., 2018), Phenotypic Age (PhenoAge), which has 72 been shown to capture long-term vulnerability to diseases like COVID-19, and 73 strongly predict morbidity and mortality risk in diverse populations (Kuo, Pilling, <sup>74</sup>Atkins, et al., 2021; Liu et al., 2018). However, it is largely unknown whether 75 PhenoAge can predict overall cancer risk and identify high risk individuals for 76 potential personalized prevention. <sup>77</sup>To date, more than 2,000 genetic loci have been identified as susceptibility markers 78 for certain cancers by genome-wide association studies (GWAS) (Buniello et al., <sup>79</sup>2019). Although the effect of these individual loci is relatively modest on cancer risk, 80 a polygenic risk score (PRS) combining multiple loci together as an indicator of 81 genetic risk has been proved to effectively predict incidence of site-specific cancer 82 (Dai et al., 2019; Lecarpentier et al., 2017; Mars et al., 2020). Recently, we <sup>83</sup>systematically created site-specific cancer PRS for 20 cancer types, and constructed

84 an incidence-weighted cancer polygenic risk score (CPRS) to assess the effect of

- 85 genetic risk on overall incident cancer risk based on the UK Biobank (Zhu et al.,
- <sup>86</sup>2021). Previous study had indicated an interaction between genetic factor and age on

and the state of th

87 cancer risk (Mavaddat et al., 2015). However, the extent to interaction between

88 genetic factor and PhenoAge on overall cancer risk remained unclear.

89 In this study, we calculated PhenoAge in accordance with the method described 90 previously and then evaluated the effectiveness of PhenoAge in predicting risk of 91 overall cancer in the UK Biobank. We also assessed the extent to which a level of <sup>92</sup>accelerated aging was associated with an increased overall cancer risk across groups 93 with a different genetic risk defined by the CPRS.

94

<sup>95</sup>**Methods**

#### <sup>96</sup>**Participants**

<sup>97</sup>The participants included in this study are derived from the UK Biobank. The UK <sup>98</sup>Biobank is a large population-based cohort study and detail protocol is publicly 99 available (Bycroft et al., 2018). In brief, approximately 500,000 participants aged <sup>100</sup>40-70 were recruited from 22 assessment centers across England, Scotland, and Wales 101 between 2006 and 2010 at baseline. Each eligible participant completed a written 102 informed consent form and provided information on lifestyle and other potentially <sup>103</sup>health-related aspects through extensive baseline questionnaires, interviews, and <sup>104</sup>physical measurements. Meanwhile, biological samples of participants were also 105 collected for biomarker assays and a blood draw was collected for genotyping. The <sup>106</sup>UK Biobank study has approval from the Multi-center Research Ethics Committee, 107 the National Information Governance Board for Health and Social Care in England 108 and Wales, and the Community Health Index Advisory Group in Scotland <sup>109</sup>(http://www.ukbiobank.ac.uk/ethics/).

#### <sup>110</sup>**PhenoAge and PhenoAgeAccel PRS**

<sup>111</sup>We calculated PhenoAge in accordance with the method described previously (Levine

112 et al., 2018). Briefly, PhenoAge was calculated based on mortality scores from the

<sup>113</sup>Gompertz proportional hazard model on chronological age and 9 multi-system clinical

- 114 chemistry biomarkers (albumin, creatinine, glucose, [log] C-reactive protein [CRP],
- <sup>115</sup>lymphocyte percent, mean cell volume, red blood cell distribution width, alkaline
- 116 phosphatase, and white blood cell count) to predict all-cause mortality. The
- 117 Biomarkers in the UK Biobank were measured at baseline (2006-2010) for all
- 118 participants. To correct distribution skewness, we set the top and bottom 1% of values
- 119 to the 99th and 1st percentiles. The formula of PhenoAge is given by

$$
\text{PhenoAge} = 141.50 + \frac{\ln\left\{(-0.00553) \times \frac{(-1.51714) \times \exp(xb)}{0.0076927}\right\}}{0.09165}
$$

#### 120 where

 $xb = -19.907 - 0.0336 \times \text{albumin} + 0.0095 \times \text{creationine} + 0.1953 \times \text{glucose}$  $+0.0954 \times \ln(CRP) - 0.0120 \times \text{lymphocyte percentage} + 0.0268$  $\times$  mean corpuscular volume  $+$  0.3306  $\times$  red blood cell distribution width(RDW) + 0.00188  $\times$  alkaline phosphatase + 0.0554  $\times$  white blood cell count  $+0.0804 \times age$ 

 $121$ 

<sup>122</sup>Finally, we calculated Phenotypic Age Acceleration (PhenoAgeAccel), which was 123 defined as the residual resulting from a linear model when regressing Phenotypic Age 124 on chronological age. Therefore, PhenoAgeAccel represents Phenotypic Age after 125 accounting for chronological age (i.e., whether a person appears older [positive value] 126 or younger [negative value] than expected, biologically, based on his/her age). 127 55 independent PhenoAgeAccel-associated SNPs  $(P < 5 \times 10^{-8})$  and corresponding 128 effect sizes were derived from a large-scale PhenoAgeAccel GWAS including 129 107,460 individuals of European ancestry (Kuo, Pilling, Liu, Atkins, & Levine, 2021). <sup>130</sup>A PhenoAgeAccel PRS was created using an additive model as previously described <sup>131</sup>(Dai et al., 2019). In short, the genotype dosage of each risk allele for each individual

132 was summed after multiplying by its respective effect size of PhenoAgeAccel.

#### <sup>133</sup>**PRS calculation and CPRS construction**

<sup>134</sup>The calculation of site-specific cancer PRSs and the construction of CPRSs have been 135 described in our previous published study (Zhu et al., 2021). In brief, for individual 136 cancer, risk associated single nucleotide polymorphisms (SNPs) and corresponding 137 effect sizes were derived from the largest published GWASs in terms of sample size. 138 Next, the dosage of each risk allele for each individual was summed after <sup>139</sup>multiplication with its respective effect size of site-specific cancer. Except for 140 non-melanoma skin cancer and those without relevant GWAS or significant genetic 141 loci published by now, we derived PRSs for 20 cancer types in this analysis. To <sup>142</sup>generate an indicator of genetic risk for overall cancer, we constructed the CPRS as 143 follows:

$$
CPRS_i = \sum_{k=1}^{K} h_k PRS_{i,k}
$$

144 Where  $CPRS_i$  is the cancer polygenic risk score of i<sup>th</sup> individual,  $h_k$  is the 145 age-standardized incidence of site-specific cancer *k* in UK population, and  $PRS_{i,k}$  is 146 the aforementioned PRS of site-specific cancer  $k$ . Given the different spectrum of 147 cancer incidence between men and women, CPRS were constructed for males and 148 females, respectively.

#### <sup>149</sup>**Assessment of healthy lifestyle**

<sup>150</sup>We adopted five healthy lifestyle factors according to the World Cancer Research

151 Fund/American Institute of Cancer Research recommendations

<sup>152</sup>(https://www.aicr.org/cancer-prevention/) (Shams-White et al., 2019), i.e., no current

- 153 smoking, no alcohol consumption, regular physical activity, moderate BMI
- <sup>154</sup>(body-mass index, 18.5~30), and a healthy diet pattern. Participants of no current
- <sup>155</sup>smoking were defined as never smoker or former smokers who had quit smoking at
- <sup>156</sup>least 30 years. No alcohol consumption was defined as never alcohol use. Regular
- 157 physical activity was defined as at least 75 minutes of vigorous activity per week or

<sup>158</sup>150 minutes of moderate activity per week (or an equivalent combination) or

159 engaging in vigorous activity once and moderate physical activity at least 5 days a

<sup>160</sup>week (Lourida et al., 2019). A healthy diet pattern was ascertained consumption of an

161 increased amount of fruits, vegetables, whole grains, fish and a reduced amount of red

<sup>162</sup>meats and processed meats (Lourida et al., 2019). The lifestyle index ranged from 0 to

<sup>163</sup>5, with higher index indicating a healthier lifestyle.

#### <sup>164</sup>**Outcomes**

165 Outcomes of incident cancer events in the UK Biobank were ascertained through

166 record electronic linkage with the National Health Service central registers and death

<sup>167</sup>registries in England, Wales and Scotland. Complete follow-up was updated to 31

168 October 2015 for Scotland, and to 31 March 2016 for England & Wales. Cancer

169 events were coded using the  $10<sup>th</sup>$  Revision of the International Classification of

170 Diseases. The outcome of all cancer events were obtained from data field 40006 and

171 40005 of the UK Biobank.

# <sup>172</sup>**Statistical analysis**

<sup>173</sup>Cancer risk of participants in the UK Biobank was assessed from baseline until to the 174 date of diagnosis, death, loss to follow-up, or date of complete follow-up, whichever 175 occurred first. Multivariable Cox proportional hazards regression analyses were 176 performed to assess associations between PhenoAgeAccel and cancer risk and to <sup>177</sup>estimate hazard ratios (HRs) as well as 95% confidence intervals (CI). Schoenfeld 178 residuals and log-log inspection were used to test the assumption of proportional 179 hazards. HRs associated with per 5 years increased of PhenoAgeAccel was calculated 180 for site-specific cancer and overall cancer respectively. We compared HRs between <sup>181</sup>biologically younger and older participants. In addition, we calculated HRs for 182 participants at low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles <sup>183</sup>2-4), and high (the top quintile) accelerated aging, and HRs for participants splitted by 184 decile of accelerated aging.

185 Meanwhile, participants were also divided into low (the bottom quintile of CPRS),

and the state of th

186 intermediate (quintiles 2-4), and high (the top quintile) genetic risk groups. Absolute 187 risk within each subgroup defined by PhenoAgeAccel and CPRS were calculated as 188 the percentage of incident cancer cases occurring in a given group. We calculated 189 absolute risk increase as the difference in cancer incidences among given groups, 190 extrapolated the difference in 5-year event rates among given groups. The 95% CIs 191 for the absolute risk increase were derived by drawing 1,000 bootstrap samples from 192 the estimation dataset. We performed additive interaction analysis between genetic 193 risk (defined by CPRS) and PhenoAgeAccel on overall cancer risk, as well as genetic <sup>194</sup>risk (defined by PhenoAgeAccel PRS) and lifestyle on PhenoAgeAccel using two <sup>195</sup>indexes: the relative excess risk due to interaction (RERI) and the attributable 196 proportion due to interaction (AP) (R. Li & Chambless, 2007). The 95% CIs of the 197 RERI and AP were estimated by bootstrap ( $N = 5,000$ ), which would contain 0 if there <sup>198</sup>was no additive interaction. We also used multivariable linear regression models to 199 assess associations between the PhenoAgeAccel and individual lifestyle factors with 200 adjustment for age, family history of cancer, Townsend deprivation index, height, and 201 the first 10 principal components of ancestry. All the above mentioned analyses were 202 performed for men and women separately.

203 Participants with missing data on any of the covariates were multiple imputed, and 204 independent analyses were also performed based on complete data for sensitivity <sup>205</sup>analyses. Besides, to examine the reliability of our results, we conducted several 206 sensitivity analyses: (1) reclassifying PhenoAgeAccel levels based on quartiles <sup>207</sup>(bottom, 2-3, and top quartiles defined as low, intermediate, and high accelerated 208 aging, respectively) or tertiles (corresponding to low, intermediate, and high 209 accelerated aging) of PhenoAgeAccel; (2) reevaluating the effect of PhenoAgeAccel 210 based on participants of unrelated British ancestry; (3) excluding incident cases of any 211 cancer occurring during the two years of follow-up; and (4) retrained PhenoAge in 212 cancer-free participants based on mortality. All *P* values were two-sided and  $P < 0.05$ 213 was considered statistically significant. All statistical analyses were performed with R 214 software, version 3.6.3 (R Project for Statistical Computing).

e de la construcción de la construcción<br>En la construcción de la const

215

#### <sup>216</sup>**Results**

#### <sup>217</sup>**Participants**

- <sup>218</sup>After removing participants who had withdrawn their consent, had been diagnosed
- 219 with cancer before baseline, failed to be genotyped, reported a mismatch sex with
- 220 genetic data, or with missing data on PhenoAge, the final analytic dataset included
- <sup>221</sup>374,463 eligible participants (173,431 men and 201,032 women). Of which, 169,573
- 222 participants were biologically older, with 92,189 men and 77,384 women, whose
- <sup>223</sup>median PhenoAgeAccel were 3.28 (interquartile range [IQR]: 1.50 to 6.06) and 3.07
- <sup>224</sup>(IQR: 1.33 to 5.79) respectively; 204,890 participants were biologically younger, with
- <sup>225</sup>81,242 men and 123,648 women, whose median PhenoAgeAccel were -2.61 (IQR:
- <sup>226</sup>-4.35 to -1.25) and -3.55 (IQR: -5.64 to -1.81) respectively (**Table 1, Appendix**
- <sup>227</sup>**1-figure 1**).

# <sup>228</sup>**Associations of PhenoAgeAccel with cancer risk**

- <sup>229</sup>There were 22,370 incident cancer cases, with 11,532 men and 10,838 women, during
- 230 a median follow-up of 7.09 years (IQR:  $6.35$  to 7.72). The PhenoAgeAccel was
- 231 significantly associated with increased risk for cancer sites of lip-oral cavity-pharynx,
- <sup>232</sup>esophagus, stomach, colon-rectum, pancreas, lung, breast, cervix uteri, corpus uteri,
- 233 prostate, kidney, bladder, multiple myeloma, Hodgkin's disease, and lymphoid
- 234 leukaemia, while negatively associated with risk of prostate cancer after adjusting for
- <sup>235</sup>chronological age and other covariates (**Figure 1, Appendix 1-table 1**).
- 236 For overall cancer, we observed an obviously higher distribution of PhenoAgeAccel
- 237 in incident cancer cases than participants without incident cancer in both men and
- 238 women (**Figure 2A** and **B**). PhenoAgeAccel was significantly associated with an
- 239 increased risk of overall cancer in men (HR =  $1.15, 95\%$  CI,  $1.13-1.17, P < 0.0001$ )
- <sup>240</sup>and women (HR = 1.15, 95% CI, 1.13-1.17, *P* < 0.0001) per 5 years increase (**Table**
- <sup>241</sup>**2**). We also observed a significantly gradient increase in incident cancer risk from
- <sup>242</sup>decile 1 to decile 10 of PhenoAgeAccel (**Figure 2C** and **D**). Compared with



<sup>244</sup>cancer, with HRs of 1.22 (95% CI, 1.18-1.27, *P* < 0.0001) in men, 1.26 (95% CI,

- <sup>245</sup>1.22-1.31, *P* < 0.0001) in women, respectively (**Figure 2E** and **F**). Besides, Compared
- 246 with individuals at low accelerated aging (the bottom quintile of PhenoAgeAccel),
- 247 those in the intermediate (quintiles  $2$  to  $4$ ) and high accelerated aging (the top quintile)
- 248 had a significantly higher risk of overall cancer, with HRs of  $1.15$  (95% CI,  $1.09-1.21$ ,
- <sup>249</sup>*P* < 0.0001) and 1.44 (95% CI, 1.36-1.53, *P* < 0.0001) in men, 1.15 (95% CI,
- <sup>250</sup>1.09-1.21, *P* < 0.0001) and 1.46 (95% CI, 1.38-1.55, *P* < 0.0001) in women,
- 251 respectively. These results did not change after adjustment for genetic risk and
- 252 lifestyle factors (**Table 2**). Similar patterns were noted in a series of sensitivity
- 253 analyses with reclassifying accelerated aging levels according to quartiles or tertiles
- <sup>254</sup>of the PhenoAgeAccel (**Appendix 1-table 2**), exclusion of incident cancer cases
- 255 occurred during the two years of follow-up (**Appendix 1-table 3**), in the unimputed
- <sup>256</sup>data (**Appendix 1-table 4**), in the unrelated British population (**Appendix 1-table 5**),
- 257 or using retrained PhenoAge in cancer-free participants (**Appendix 1-table 6**).

# <sup>258</sup>**Joint effect and interaction of genetic factor and PhenoAgeAccel on overall**

#### <sup>259</sup>**cancer risk**

<sup>260</sup>The overall incident cancer risk associated with both genetic risk and PhenoAgeAccel

261 in a dose-response manner (**Figure 3**). Of participants with high genetic risk and older

262 PhenoAge, the incidence rates of overall cancer per 100,000 person-years were

263 estimated to be 1477.89 (95% CI, 1410.87-1544.92) in men and 1076.17 (95% CI,

<sup>264</sup>1014.14-1138.19) in women versus 581.06 (95% CI, 537.12-625.00) in men and

<sup>265</sup>594.71 (95% CI, 558.50-630.92) in women with low genetic risk and younger

- 266 PhenoAge. Approximate double risks [HR, 2.29 (95% CI, 2.10-2.51) in men,  $P \leq$
- <sup>267</sup>0.0001; 1.94 (95% CI, 1.78-2.11) in women, *P* < 0.0001] were observed in
- 268 participants with high genetic risk and older PhenoAge, compared with those with
- 269 low genetic risk and younger PhenoAge. Similar patterns were noted by reclassifying
- 270 accelerated aging levels into low (the bottom quintile of PhenoAgeAccel),
- 271 intermediate (quintiles 2-4), and high (the top quintile) (**Appendix 1-figure 2**).

- <sup>272</sup>However, we did not observe interaction between genetic and PhenoAgeAccel on
- 273 overall cancer risk in men and women (**Appendix 1-table 7**).

# <sup>274</sup>**Disadvantages of older PhenoAge with overall incident cancer**

275 In further stratification analyses by genetic risk category with younger PhenoAge as

- 276 the reference group, we confirmed that older PhenoAge was significantly associated
- <sup>277</sup>with a higher incident cancer risk across genetic risk groups (**Table 3**). Among
- 278 participants at high genetic risk, the standardized 5-year incident cancer rates were
- <sup>279</sup>5.78% and 4.58% for biologically younger men and women versus 6.90% and 5.17%
- 280 for those older, respectively. Similarly, among participants at low genetic risk, the
- 281 standardized 5-year incident cancer rates increased from 2.71% and 2.83% for
- <sup>282</sup>biologically younger to 3.87% and 3.39% for those older in men and women,
- 283 respectively. Similar patterns were noted by reclassifying accelerated aging levels into
- 284 low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2-4), and high
- <sup>285</sup>(the top quintile) (**Appendix 1-table 8**).
- 286 In addition, to evaluate the implication for cancer screening in populations with
- 287 different PhenoAgeAccel, we estimated the 5-year absolute risk of overall cancer
- 288 between biologically younger and older participants with the increasing of age.
- 289 Assuming 2% of absolute risk within the next 5 years as the threshold to be
- 290 recommended for cancer screening, biologically younger men would reach the
- 291 threshold at age 52, whereas those older men would reach the threshold at age 50;
- 292 similarly, biologically younger women would reach the 2% of 5-year absolute risk at
- <sup>293</sup>age 46, whereas those older women would reach the threshold at age 44 (**Figure 4**).

#### <sup>294</sup>**Associations of lifestyle factors with PhenoAgeAccel**

- 295 In the UK Biobank, biologically younger men (9.6%, 7,781/81,242) and women
- 296  $(14.4\%, 17.781/123,648)$  were more likely to have favorable lifestyle (4 to 5 healthy
- 297 lifestyle factors) than older men  $(5.7\%, 5,255/92,189)$  and women  $(9.3\%,$
- <sup>298</sup>7,178/77,384) (**Table 1**). Among both men and women, we observed that
- <sup>299</sup>PhenoAgeAccel decreased with the increase of healthy lifestyle factors (**Appendix**

<sup>300</sup>**1-table 9**). In addition, we found a significant negative correlation between the

301 number of healthy lifestyle factors and PhenoAgeAccel (Beta  $=$  -1.01 in men, *P* <

<sup>302</sup>0.001; Beta = -0.98 in women, *P* < 0.001) (**Appendix 1-table 10**). However, we did

303 not observe any interaction between genetic risk and lifestyle on PhenoAgeAccel in

- <sup>304</sup>both men and women (**Appendix 1-table 11**).
- 305

#### <sup>306</sup>**Discussion**

307 In this study, we calculated PhenoAgeAccel to explore the effect of accelerated aging 308 on the risk of cancer, and demonstrated a positive association between accelerated 309 aging and increased cancer risk after adjustment for chronological age in the UK <sup>310</sup>Biobank. Meanwhile, older PhenoAge was consistently associated with an increased 311 absolute risk of incident cancer within each genetic risk group; and participants with 312 high genetic risk and older PhenoAge had the greatest incident cancer risk. Therefore, 313 our findings provided the evidence for PhenoAgeAccel to be used for risk 314 stratification of cancer, which were independent from genetic risk. Moreover, we also 315 demonstrated that participants with older biological age often reaches the screening 316 threshold 2 years in advance compared with biologically younger peers; and keeping a 317 healthy lifestyle can effectively slow down the aging process. <sup>318</sup>Older age has been long recognized as the main risk factor for cancer, and the <sup>319</sup>multistage model of carcinogenesis posits that the exponential increase in cancer 320 incidence with age were mainly resulted from the sequential accumulation of 321 oncogenic mutations in different tissues throughout life (Laconi, Marongiu,  $\&$ <sup>322</sup>DeGregori, 2020). In consistent with this, age and exposure (i.e. smoking, ultraviolet

<sup>323</sup>light) dependent mutation signatures have been identified in several cancers by tissue

324 sequencing (Alexandrov et al., 2020). However, biological aging is an enormously

325 complex process and is thought to be influenced by multiple genetic and

326 environmental factors (van Dongen et al., 2016). Therefore, several biomarkers, i.e.

<sup>327</sup>'ageing clocks' derived from epigenomic, transcriptomic, proteomic and metabolomic

13

328 data, have been proposed to measure the biological age and predict risk of cancer and 329 other diseases (Rutledge et al., 2022; Zhang et al., 2022). However, these measures 330 were usually based on omics data and was not suitable for application in large 331 population by now. As a result, results from this study would provide a cost-effective 332 indicator for measuring of biological age as well as a novel biomarker for cancer risk 333 prediction.

<sup>334</sup>The associations between biological age and cancer risk has been investigated by 335 several studies recently. Li et al. explored three DNA methylation phenotypic age and 336 cancer risk in four subsets of a population-based cohort from Germany, and reported 337 strong positive associations for lung cancer, while strong inverse associations for 338 breast cancer (X. Li, Schottker, Holleczek, & Brenner, 2022). Meanwhile, results 339 from Melbourne Collaborative Cohort Study reported that epigenetic aging was 340 associated with increased cancer risk of kidney cancer and B-cell lymphoma (Dugue) 341 et al., 2018). However, because of sample size, the association results were still <sup>342</sup>inconsistent for DNA methylation phenotypic age among different studies. Leukocyte 343 telomere length was also significantly associated with age and were regarded as an 344 indicator of aging. Based on data from the UK Biobank, Schneider et al. recently 345 explored the associations between telomere length and risk of several disease, and 346 reported significant positive associations of telomere length for lymphoid leukemia, <sup>347</sup>multiple myeloma, non-Hodgkin lymphoma, esophagus cancer, while negative <sup>348</sup>associations for malignant neoplasm of brain, mesothelioma, and melanoma <sup>349</sup>(Schneider et al., 2022). The positive associations were in consistent with our findings, 350 however, the negative associations were not significant in our study. Meanwhile, the 351 study did not indicate associations for other cancers, including cancers of lung, 352 stomach, pancreases, and kidney, which showed relatively large effects (HR  $> 1.3$ ) in 353 our study. These findings indicated that the different measures of biological age may 354 reflect the different aspects of aging, and could be joint application in cancer risk 355 assessment.

<sup>356</sup>Recently, several studies have confirmed the associations between PhenoAgeAccel

14 - Paul III, markanista kanademik (h. 1440).<br>14 - Johann Barnett, markanista kanademik (h. 1440).

<sup>357</sup>and cancer risk. Mak et al. explored three measures of biological age, including <sup>358</sup>PhenoAge, and assessed their associations with the incidence of overall cancer and 359 five common cancers (breast, prostate, lung, colorectal, and melanoma) (Mak et al., <sup>360</sup>2023). In our previous study, we investigated the association between PhenoAgeAccel 361 and lung cancer risk and analyzed the joint and interactive effects of PhenoAgeAccel 362 and genetic factors on the risk of lung cancer (Ma et al., 2023). In comparison to these 363 studies, our analysis expanded the range of cancers to 20 types and further explored 364 the associations in different genetic and lifestyle contexts. Moreover, we also 365 evaluated the potential implications of PhenoAge in population-level cancer screening. <sup>366</sup>In addition, we observed a negative association between PhenoAgeAccel and prostate 367 cancer risk. The unexpected association may have been confounded by diabetes and 368 altered glucose metabolism, both of which are closely linked to aging. When we 369 removed HbA1c and serum glucose from the biological age algorithms, the 370 association became non-statistically significant. Similar findings were also reported 371 by Mak et al. (Mak et al., 2023) and Dugue et al. (Dugue et al., 2021). <sup>372</sup>The associations between PhenoAgeAccel and increased cancer risk may be partly 373 attribute to a result of decline in the immune system and accumulation of <sup>374</sup>environmental carcinogenic factors. Recent GWASs of PhenoAgeAccel showed that <sup>375</sup>SNPs associated with PhenoAgeAccel were enriched in pathways of immune system 376 and activation of pro-inflammatory (Kuo, Pilling, Liu, Atkins, & Levine, 2021; <sup>377</sup>Levine et al., 2018). In addition to genetics, behaviors (i.e. obesity, smoking, alcohol 378 consumption, and physical activity), and life course circumstances (i.e. 379 socioenvironmental circumstances during childhood and adulthood) were reported to 380 account for about 30% variances of phenotypic aging (Liu et al., 2019). This was in 381 accordance with our findings that, adherence to healthy lifestyles (involving no 382 current smoking, normal BMI, regular physical activity, and healthy diet) could slow 383 down the aging process. In other words, these healthy lifestyles considered in our and <sup>384</sup>previous studies may be causal drivers of phenotypic aging, they represent a more 385 targetable strategy for reducing overall cancer burden by retarding the aging process.

15

<sup>386</sup>Therefore, PhenoAge provide a meaningful intermediate phenotype that can be used 387 to guide interventions for high risk groups and track intervention efficacy (Liu et al., <sup>388</sup>2019).

This study has several strengths, including a large sample size, a prospective design of 390 the UK Biobank study, and an effective application of PhenoAgeAccel in predicting 391 risk of overall cancer. Nevertheless, we also acknowledge several limitations. First, we calculated PhenoAge based on 9 biomarkers from blood, which were measured at baseline. As such, we were unable to access the change of PhenoAgeAccel during the 394 follow-up period. Second, previous studies have indicated that patricians in the UK Biobank differ from the general UK population because of low participation and healthy volunteer bias (Fry et al., 2017). Finally, even though the findings were achieved from participants with diverse ethnic backgrounds of the UK Biobank, the generalizability of our findings should be further assessed in more diverse populations when available.

400 In summary, our study showed that accelerated aging, which was measured by

<sup>401</sup>PhenoAgeAccel, was consistently related to an increased risk of several site-specific

<sup>402</sup>cancer and overall cancer with adjustment for chronological age, within and across

<sup>403</sup>genetic risk groups. PhenoAgeAccel can serve as a productive tool to facilitate

404 identification of cancer susceptible individuals, in combination with individual's

<sup>405</sup>genetic background, and act as an intermediate phenotype to guide interventions for

406 high risk groups and track intervention efficacy.

407

<sup>408</sup>**Ethics approval and consent to participate:** This research was conducted using the <sup>409</sup>UK Biobank Resource (Application Number: 60169). UK Biobank has received 410 ethics approval from the Research Ethics Committee (ref. 11/NW/0382).

<sup>411</sup>**Availability of data and materials:** The data underlying the results presented in the 412 study are available from the UK Biobank (http://biobank.ndph.ox.ac.uk/showcase/).

<sup>413</sup>**Competing interests:** The authors declare that they have no competing interests.

16 - Paul Barbara, politikar eta biztanleria (h. 1654).<br>16 - Jan Barbara, politikar eta biztanleria (h. 1654).

- <sup>414</sup>**Funding:** This work was supported by National Natural Science Foundation of China
- <sup>415</sup>(82230110, 82125033 to GJ; 82273714 to MZ); and the Excellent Youth Foundation
- 416 of Jiangsu Province (BK20220100 to MZ).

#### <sup>417</sup>**Authors' Contributions**

- <sup>418</sup>**L. Bian**: Data curation, formal analysis, validation, visualization, writing–original
- <sup>419</sup>draft, writing–review and editing. **Z. Ma**: Data curation, formal analysis, validation,
- 420 visualization, writing–review and editing. **X. Fu**: Data curation, validation,
- <sup>421</sup>visualization, writing–review and editing. **C. Ji**: Data curation, validation,
- <sup>422</sup>visualization. **T. Wang**: Methodology, formal analysis, validation, visualization,
- <sup>423</sup>writing–review and editing. **C. Yan**: Methodology, writing–review and editing. **J. Dai**:
- <sup>424</sup>Methodology, writing–review and editing. **H. Ma**: Supervision, project administration,
- <sup>425</sup>writing–review and editing. **Z. Hu**: Conceptualization, supervision, project
- <sup>426</sup>administration, writing–review and editing. **H. Shen**: Conceptualization, resources,
- <sup>427</sup>supervision, project administration, writing–review and editing. **L. Wang**:
- <sup>428</sup>Conceptualization, formal analysis, supervision, validation, writing–review and
- 429 editing. **M. Zhu**: Conceptualization, formal analysis, supervision, funding acquisition,
- 430 validation, writing–original draft, writing–review and editing. **G. Jin**:
- <sup>431</sup>Conceptualization, formal analysis, supervision, funding acquisition, validation,
- 432 writing–review and editing.

#### <sup>433</sup>**Acknowledgments**

- <sup>434</sup>The authors thank the investigators and participants in UK Biobank for their
- 435 contributions to this study.

- **Australia de Ferences**<br>1987 Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., . . . Consortium, P. 438 (2020). The repertoire of mutational signatures in human cancer. Nature, 578(7793), 94-1<br>439 (300). The repertoire of mutational signatures in human cancer. Nature, 578(7793), 94-1<br>440 Bray, F., Ferlay, J., Soerjomatar 438 (2020). The repertoire of mutational signatures in human cancer. Nature, 578(7793), 94-101.<br>439 (apply 1.0.1038/s41586-020-1943-3)<br>440 (apply 1.5 Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Glob
- 
- Bray, F., Ferlay, J., Soerjomataram, I., Siege<br>441 statistics 2018: GLOBOCAN estima<br>442 185 countries. CA Cancer J Clin, 68<br>443 Buniello, A., MacArthur, J. A. L., Cerezo, M.<br>444 (2019). The NHGRI-EBI GWAS Cata
- 441 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 can<br>185 countries. CA Cancer J Clin, 68(6), 394-424. doi: 10.3322/caac.21492<br>443 Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. 1442 Statistics 2018: CA Cancer J Clin, 68(6), 394-424. doi: 10.3322/caac.21492<br>
443 Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., . . . Parkinson, H.<br>
444 (2019). The NHGRI-EBI 443 Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone,<br>444 (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association<br>17 144 Bunner, A., MacArthur, J. A. L., Cerezo, M., Harris, L. M., Hayhurst, J., Malangone, C., . . . . . . . . .<br>444 (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies,<br>17  $4444$  (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies,







# <sup>529</sup>**Table 1. Baseline characteristics of participants stratified by PhenoAgeAccel categories**



<sup>a</sup> Healthy lifestyle was defined as favorable (4-5 healthy lifestyle factors), intermediate (2-3 healthy lifestyle factors), and unfavorable (0-1 healthy lifestyle

531 factor).



# <sup>532</sup>**Table 2. Association between PhenoAgeAccel and cancer risk**

533 <sup>a</sup> Cox proportional hazards regression adjusted for age, height, cancer family history, Townsend deprivation index at recruitment, and the first 10 principal

534 components of ancestry.

<sup>b</sup> Cox proportional hazards regression adjusted for Model 1, as well as cancer polygenic risk score and healthy lifestyle.

536 C befined by quintiles of PhenoAgeAccel: low (the bottom quintile), intermediate (quintiles 2-4) and high (the top quintile).

537 Abbreviations: CI, confidence interval; HR, hazards ratio; Ref, reference.



# **Table 3. Risk of incident cancer according to PhenoAgeAccel categories within each genetic risk level a** <sup>538</sup>

<sup>a</sup>Cox proportional hazards regression is adjusted for age, height, family history of cancer, Townsed deprivation index, height and the first 10 principal

540 components of ancestry.

541 Abbreviations: CI, confidence interval; Ref, reference.

# <sup>542</sup>**Figure legends**

# 543 **Figure 1. Association results of PhenoAgeAccel with site-specific cancer risk per** 5 **vears increased.** Cox proportional hazards regression adjusted for age, height,

5 years increased. Cox proportional hazards regression adjusted for age, height,<br>545 cancer family history. Townsend deprivation index at recruitment, and the first 1

545 cancer family history, Townsend deprivation index at recruitment, and the first 10<br>546 principal components of ancestry.

546 principal components of ancestry.<br>547

# 548 **Figure 2. Effect of PhenoAgeAccel on the risk of incident cancer in the UK**<br>549 **Biobank**. The distrubution of PhenoAgeAccel between participants with incident

549 Biobank. The distrubution of PhenoAgeAccel between participants with incident<br>550 cancer and those without incident cancer in the UK Biobank for men(A) and wom

- 550 cancer and those without incident cancer in the UK Biobank for men $(A)$  and women (B). Participants in the UK Biobank were divided into ten equal groups according to
- 551 (B). Participants in the UK Biobank were divided into ten equal groups according to<br>552 the PhenoAgeAccel for men (C) and women (D), and the hazard ratios (HRs) of each
- 552 the PhenoAgeAccel for men (C) and women (D), and the hazard ratios (HRs) of each<br>553 group were compared with those in the bottom decile of PhenoAgeAccel. Error bars
- 553 group were compared with those in the bottom decile of PhenoAgeAccel. Error bars<br>554 are 95% CIs. Standardized rates of cancer events in vounger and older PhenoAge
- 554 are 95% CIs. Standardized rates of cancer events in younger and older PhenoAge<br>555 groups in the UK Biobank for men (E) and women (F). HRs and 95% CIs were
- 555 groups in the UK Biobank for men (E) and women (F). HRs and 95% CIs were<br>556 estimated using Cox proportional hazard models with adjustment for age, height
- 556 estimated using Cox proportional hazard models with adjustment for age, height,<br>557 family history of cancer. Townsend deprivation index, and the first 10 principal
- 557 family history of cancer, Townsend deprivation index, and the first 10 principal<br>558 components of ancestry. Shaded areas are 95% CIs. 558 components of ancestry. Shaded areas are 95% CIs.<br>559
- 

# 559 <sup>560</sup>**Figure 3. Risk of incident cancer according to genetic and PhenoAgeAccel**

# 561 **categories in the UK Biobank for men (A) and women (B).** The HRs were estimated using Cox proportional hazard models with adjustment for age, heir

- 
- 562 estimated using Cox proportional hazard models with adjustment for age, height,<br>563 family history of cancer. Townsend deprivation index, and the first 10 principal
- 563 family history of cancer, Townsend deprivation index, and the first 10 principal<br>564 components of ancestry. Participants were divided into younger and older Phenc 564 components of ancestry. Participants were divided into younger and older PhenoAge<br>565 under different genetic risk groups.
- 565 under different genetic risk groups.<br>566
- 

567 **Figure 4. Absolute risk estimates of overall cancer based on the UK Biobank for men (A) and women (B).** The x-axis is chronological age. The curves describe

568 **men (A) and women (B).** The x-axis is chronological age. The curves describe<br>569 average risk of participants in vounger and older PhenoAge groups. The dashed

569 average risk of participants in younger and older PhenoAge groups. The dashed curve<br>570 represents the average risk of the whole population in different ages. The red

- 570 represents the average risk of the whole population in different ages. The red<br>571 horizontal dotted line represents 2% of 5-vear absolute risks of overall cancer
- 571 horizontal dotted line represents 2% of 5-year absolute risks of overall cancer.<br>572
- 





 $0.025$ 

 $0.000$ 

 $\dot{\mathfrak{o}}$ 

 $7.5$ 

 $\frac{2.5}{2.5}$  Years of Follow-up

 $7.5$ 

 $0.000$ 

 $\dot{\mathbf{0}}$ 

 $\frac{2.5}{2.5}$  Years of Follow-up

medRxiv preprint doi: [https://doi.org/10.1101/2023.09.27.23296204;](https://doi.org/10.1101/2023.09.27.23296204) this version posted February 22, 2024. The copyright holder for this pr





